Design Therapeutics to Participate in Two Investor Conferences

• FibroBiologics Outperformance: FibroBiologics, Inc. (FBLG) surged 7.68% in after-hours trading to close at $0.41, indicating speculative interest or technical momentum despite no specific news.
• Nyxoah Earnings Boost Confidence: Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary Q4 and full-year 2025 results, with guidance for Q1 2026 enhancing investor confidence in its growth trajectory.
• Fortress Biotech's Continued Volatility: Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49 in after-hours trading, continuing a trend of volatility without any fresh news impacting the stock.
• Revvity Collaboration Drives Growth: Revvity, Inc. (RVTY) posted a 4.92% gain to close at $109.00, as investors digest the January announcement of a collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform.

• UroGen Pharma Options Activity: UroGen Pharma Ltd (URGN) has seen a significant options volume of 20,539 contracts today, equating to about 2.1 million underlying shares, which is 192% of its average daily trading volume over the past month.

• High Volume Call Option for URGN: The $24 strike call option expiring on February 20, 2026, has particularly high activity with 10,010 contracts traded, representing approximately 1.0 million underlying shares.

• Design Therapeutics Options Activity: Design Therapeutics Inc (DSGN) has recorded an options volume of 5,000 contracts today, representing around 500,000 underlying shares, which is 164.8% of its average daily trading volume over the past month.

• High Volume Call Option for DSGN: The $9 strike call option expiring on January 16, 2026, has seen all 5,000 contracts traded today, corresponding to approximately 500,000 underlying shares.

• Investor Conference Participation: Design Therapeutics will participate in the Piper Sandler and Evercore annual healthcare conferences on December 3 and 4, 2025, respectively, in New York and Coral Gables, showcasing its latest advancements in gene-targeted therapies to attract more investor interest in its clinical-stage biotechnology innovations.
• Live Webcasts Available: Each conference will feature live webcasts accessible through the company’s website, archived for at least 30 days post-event, ensuring that investors unable to attend in person can still access critical information, thereby enhancing the company's transparency and investor relations.
• Technology Platform Introduction: The GeneTAC® platform focuses on developing treatments for serious degenerative genetic diseases, particularly clinical-stage projects like DT-216P2 and DT-168, which are expected to draw interest from investors focused on gene therapy, further bolstering the company's influence in the biotechnology sector.
• Multiple R&D Projects: In addition to existing clinical programs, Design Therapeutics is advancing DT-818 for myotonic dystrophy type-1 and exploring treatments for Huntington's disease, demonstrating its broad R&D capabilities in gene therapy, which could provide strong momentum for future growth.

• U.S. Stock Market Performance: U.S. stocks rose, with the Dow Jones increasing by over 250 points, driven by strong earnings reports from several companies.

• Nutex Health Inc Surge: Nutex Health's shares jumped 37.3% after reporting quarterly sales of $267.804 million, significantly exceeding market expectations.

• Other Notable Stock Gains: PACS Group, Cerence Inc, and Exact Sciences Corp also saw substantial increases in their stock prices following positive financial results and forecasts.

• Walmart's Positive Outlook: Walmart's shares rose 6.5% after reporting strong third-quarter results and raising its revenue and earnings outlook for FY26, along with plans to transfer its listing to Nasdaq.

Steven Cohen's Biotech Investments

• Point72 Asset Management's New Stakes: Billionaire hedge fund manager Steven Cohen is making significant investments in small-cap biotech firms, particularly focusing on companies with promising genetic and antibody therapies. His firm has recently acquired stakes in Invivyd Inc. and Design Therapeutics Inc., capitalizing on their recent stock performance.

• Invivyd Inc. Investment: Point72 disclosed a new position in Invivyd, purchasing 16.73 million shares for $17.23 million at an average price of $1.03. Invivyd's stock has surged 106% year-to-date, with a notable 22% increase in the past month. Despite being below its 52-week high of $2.74, the stock has rebounded from a low of 35 cents, driven by optimism surrounding its monoclonal antibody candidate VYD222.

• Design Therapeutics Stake Increase: Cohen's firm increased its stake in Design Therapeutics by 62.8%, acquiring an additional 1.14 million shares. The current stake is valued at approximately $5.64 per share, reflecting a 24% increase from the initial entry price of $4.55. Design Therapeutics has seen its shares rise nearly 42% in the past month and 19.8% over the past year, with its GeneTACTM molecules targeting specific genetic diseases.

Market Trends and Future Outlook

• Growing Hedge Fund Interest: Cohen's investments highlight a broader trend of hedge funds seeking high-risk, high-reward opportunities in the biotech sector. The market response to small-cap biotech stocks indicates a growing appetite for innovative therapies, particularly as these companies show potential for significant breakthroughs.

• Performance of Other Biotech Stocks: Alongside Invivyd and Design Therapeutics, Cohen has also invested in Structure Therapeutics and Entrada, which are gaining traction in the market. The performance of these stocks in 2025 suggests that investors are increasingly optimistic about the future of small-cap biotech investments.

• Design Therapeutics Update: Design Therapeutics will present an update on its DT-168 program for Fuchs endothelial corneal dystrophy at the Eyecelerator conference on May 2, 2025, highlighting safety findings from Phase 1 trials and plans for Phase 2 development.

• GeneTAC® Technology: DT-168 is a GeneTAC® small molecule eye drop aimed at targeting the TCF4 gene mutation responsible for FECD, with potential to restore endothelial function in patients suffering from this progressive corneal disease.